Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.01
-$0.05(-2.00%)
At close: 4:00 PM EST
$19.01
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.33 - $24.28
Previous CloseN/A
Volume148.24K
Average Volume (3M)6.76M
Market Cap
$5.74B
Enterprise Value$4.35B
Total Cash (Recent Filing)$243.79M
Total Debt (Recent Filing)$45.95M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding310,984,530
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.96K
Enterprise Value/Ebitda-16.05
Forecast
1Y Price Target
$22.25Price Target Upside17.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthErasca's balance sheet shows relatively low leverage (~0.12 D/E) and a sizable equity base (~$393.5M TTM), which provides durable financial flexibility for a clinical-stage biotech. This supports continued R&D spending, trial enrollment and strategic options without immediate insolvency risk, lengthening runway versus peers relying on rapid financing.
Promising Clinical DataEncouraging Phase 1 data for ERAS-0015 (defined active dose range, consistent pharmacokinetics, strong ctDNA declines and high early response rates across tumor types) materially de-risks the lead program. Over months this strengthens the company's ability to advance to expansion/combination cohorts, attract partners, and prioritize resources toward potentially best-in-class assets.
Governance ContinuityReelection of experienced directors and ratification of KPMG provide durable governance stability and credible financial oversight. For a development-stage firm, consistent board oversight and reputable audit relationships reduce execution and reporting risk, aiding strategic decisions around clinical development, partnering, and capital raises over the coming quarters.
Bears Say
Cash Burn & Negative Cash FlowSustained and worsening negative operating and free cash flow (TTM ~ -$91M) creates persistent runway pressure that is structural for a clinical-stage biotech. Over the medium term this necessitates additional financing or partnerships, which can dilute shareholders, constrain program timing, or force prioritization among pipeline programs if capital markets are unfavorable.
Legal / IP Risk To Lead AssetAn asserted patent and trade-secret dispute over ERAS-0015 introduces a structural execution risk: litigation can delay trials, increase costs materially, restrict U.S. activities or prompt injunctions, and chill potential partnerships or commercial planning. This uncertainty around a core program can alter pipeline value and strategic options for months to years.
No Commercial Revenue; Funding DependenceAs a clinical-stage company with no approved products, Erasca relies on external financing, collaborations and milestone payments. Structurally, this creates recurring dilution and dependency on partner milestones or capital markets to fund operations. Over multiple quarters this constraint can limit strategic freedom and elevates execution risk if trials or partner talks stall.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.33 and its highest was $24.28 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $5.74B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on May 11, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.496.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.11.
How many shares outstanding does Erasca have?
Erasca has 310,984,530 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.25 (17.04% Upside)
$22.25 (17.04% Upside)
Hedge Fund Trend
Increased
By 965.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
400.50%
12-Months-Change
Fundamentals
Return on Equity
-77.01%
Trailing 12-Months
Asset Growth
-2.12%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$22.25
▲(17.04% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
10.85% Insiders
12.76% Mutual Funds
55.53% Other Institutional Investors
9.27% Public Companies and
Individual Investors